Dietary Sodium (DS) Intervention to Reduce Volume Overload and Tissue Sodium in Magnetic Resonance Imaging (MRI) for Hemodialysis (HD) Patients

Kidney Failure, Chronic Clinical Trial

— DSMRI  

Official title:

Dietary Sodium (DS) Intervention to Reduce Volume Overload and Tissue Sodium in Magnetic Resonance Imaging (MRI) for Hemodialysis (HD) Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03189758
• Other study ID #: 17530
• Status: Recruiting
• Phase: N/A
• Start date: June 19, 2017
• Est. completion date: December 31, 2021

Study information

• Verified date: July 2020
• Source: University of Illinois at Urbana-Champaign
• Contact: Luis M Perez, BS
• Phone: 7192444805
• Email: lmperez2[@]illinois.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Sodium-adapted magnetic resonance imaging (23Na-MRI) studies have demonstrated that sodium accumulates in certain tissues, including the skin and skeletal muscle, but may be manipulated by lifestyle factors or therapeutic interventions such as a hemodialysis (HD) session. This tissue sodium accumulation is increased with age and in the presence of certain chronic diseases such as renal failure, and may contribute to the development of high blood pressure. It currently not known what the impact of dietary sodium consumption has on tissue sodium in HD patient's and on the subsequent risk of cardiovascular complications either acutely or chronically. The University of Illinois' Biomedical Imaging Center recently completed safety testing on a 23Na-MRI coil that they modified for measuring skin and muscle sodium levels in the lower leg/calf that will be used for assessing the impact of dietary salt restriction on tissue sodium levels.

Description:

Recent studies illustrate that tissue sodium is regulated by immune cells in interstitial fluids such as the skin and muscle. Localized immune responses in these tissues can promote vascular endothelial growth factor secretion to promote lymphatic release of fluid and electrolytes, which has significant implications for blood pressure control and cardiovascular health. Furthermore, sodium composition of the diet has the potential to promote beneficial gut bacteria in addition to lowering auto-immune response and blood pressure.

The purpose of this pilot study is to utilize this 21Na-MRI coil to quantify changes of sodium levels in the skin and skeletal muscle in hemodialysis treatments before and after a low-sodium diet intervention. In this study, all HD patients will undergo a 30-day observation period (CON) followed by a low-sodium diet period (INT) for 30 additional days. Testing will occur at baseline and after each time-point (three time points total). During the CON period, patients will have no changes to their normal dialysis treatment, and will be asked to follow their normal diet. During the INT period, patients will provided a low- sodium diet intervention that includes receiving 3 low sodium meals per day and snacks provided by momsmeals.com.

The study outcomes include: clinical outcomes (hospitalizations, treatment efficiency) changes in tissue sodium, cardiovascular measures (blood pressure, cardiac output, and vascular resistance) and fluid/hydration status (total body water, extracellular fluid) using bioelectrical impedance. We will also collect serum to analyze the relationship between changes in tissue sodium and serum minerals (e.g. sodium and potassium), and other factors believed to help regulate tissue sodium levels, including vascular endothelial growth factor (VEGF), and markers of inflammation (CRP, IL-6). Additionally, we plan to collect patient stool samples to analyze how changes in dietary sodium consumption impact the gut microbiome.

This study will demonstrate the feasibility of utilizing 23Na-MRI to quantify skin and muscle sodium levels, as well as provide pilot data regarding the relationship between tissue sodium accumulation, inflammation, the gut microbiome, insulin resistance, and cardiovascular health in hemodialysis patients. Results from this study will then be used to design larger trials to investigate related questions.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Willingness to sign informed consent document and age 18 or greater.

• Willingness to consume intervention meals 3 times per day (with provided snacks) for 30 days.

Exclusion Criteria:

1. Individuals with pacemakers (exclusion from cardiovascular testing only)

2. Individuals with major amputations (i.e. whole limb: foot, ankle, leg, arm)

3. Individuals with ferric metal implants or devices in the body (excluded from MRI testing only)

4. Claustrophobic individuals (excluded from MRI testing only)

5. Individuals that do not otherwise meet MRI screening requirements (mentioned below, excluded from MRI testing only)

6. Individuals on HD therapy <3 days per week or <3 months

7. Currently following a sodium restricted diet approximately <1,500 mg per day (only excluded from MRI analysis)

8. Currently diagnosed GI disorder or disease or infection

Related Conditions & MeSH terms

• Dietary Modification
• Kidney Failure, Chronic
• Renal Insufficiency

Intervention

Other:
• Observational Control Diet
Participants will follow their usual or normal diet for 30 days (days 1-30) while under study observation.
• Controlled Dietary Sodium Restriction
Participants will be provided with all meals and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg & 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (<2,000g/day) and will be ordered and delivered through momsmeals.com

Locations

Country	Name	City	State
United States	University of Illinois at Urbana-Champaign	Urbana	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
University of Illinois at Urbana-Champaign	Renal Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Interdialytic weight gain	Interdialytic weight from clinic records	28 days
Primary	Tissue sodium	MRI detected sodium content in the lower leg (mM)	28 days
Secondary	Hydration status	Bio-impedance measured total body water, extracellular fluid, intracellular fluid, and calculated fluid volume overload	28 days
Secondary	Cardiovascular function	Standard blood pressure	28 days
Secondary	Biochemical markers	Vascular endothelial growth factor-C (VEGF-C), C-reactive protein (CRP), interleukin (IL-6), tumour necrosis factor alpha (TNF-a), endothelial nitric oxide (eNOS), serum sodium (Na)	28 days
Secondary	Gut microbiome (stool sample)	DNA sequencing, bacteria phyla and taxa, stool consistency, gastrointestinal symptoms	28 days